Atossa Therapeutics Presents Data from 40mg Cohort of Phase
SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and...
Source: globenewswire.com
Nusaybaa Bagegni News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nusaybaa Bagegni. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nusaybaa Bagegni Today - Breaking & Trending Today
Practice-Changing Trials Expand Armamentarium and Improve Guidance in Advanced Breast Cancers
Several landmark trials have led to FDA approval milestones across all breast cancer subtypes in the past 5 years, each continuing to change the navigation of treatment approaches in clinical practice.
Source: onclive.com
Research on Current and Emerging HER2-targeted Agents Continues to Advance Breast Cancer Treatment
Cynthia X. Ma, MD, PhD, discusses updates in triple-negative breast cancer treatment, recent data on HER2-targeted agents in metastatic and early-stage HER2-positive breast cancer, and the role of CDK4/6 inhibitors and oral selective estrogen receptor degraders in hormone receptor–positive disease.
Source: onclive.com
State of Science Summit- Breast Cancer: Chaired by Cynthia X Ma, MD, PhD & Foluso O. (Bisi) Ademuyiwa, MD, MPH, MSCI
State of Science Summit- Breast Cancer: Chaired by Cynthia X Ma, MD, PhD & Foluso O. (Bisi) Ademuyiwa, MD, MPH, MSCI
Source: onclive.com
Biovica International: Biovica's DiviTum TKa featured in TK IMPACT study at SABCS
UPPSALA, SE / ACCESSWIRE / November 22, 2022 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) Biovica, active in cancer monitoring, today announces that the unique study design of the TK
Source: finanznachrichten.de